ARTV
Artiva Biotherapeutics, Inc. Common StockARTV
ARTV
About: Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Employees: 89
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 6
19% more funds holding
Funds holding: 48 [Q3] → 57 (+9) [Q4]
1.9% more ownership
Funds ownership: 85.22% [Q3] → 87.12% (+1.9%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
33% less capital invested
Capital invested by funds: $319M [Q3] → $213M (-$106M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
704%
upside
Avg. target
$20
804%
upside
High target
$23
927%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Needham Gil Blum 12% 1-year accuracy 19 / 157 met price target | 927%upside $23 | Buy Reiterated | 8 Apr 2025 |
HC Wainwright & Co. Edward White 24% 1-year accuracy 36 / 149 met price target | 793%upside $20 | Buy Reiterated | 26 Mar 2025 |
Wedbush Martin Fan 50% 1-year accuracy 1 / 2 met price target | 704%upside $18 | Outperform Reiterated | 25 Mar 2025 |
Cantor Fitzgerald Josh Schimmer 20% 1-year accuracy 11 / 54 met price target | 793%upside $20 | Overweight Maintained | 25 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ARTV published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy
Neutral
GlobeNewsWire
2 weeks ago
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 11:00 a.m. EDT.
Neutral
GlobeNewsWire
3 weeks ago
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025 Strengthened key leadership with cell therapy and autoimmune expertise across organization Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress. “2024 was a transformational year for Artiva including initiating dosing of AlloNK® in patients with autoimmune disease across our trials, a successful initial public offering strengthening our balance sheet, and expanding key leadership across the organization with expertise in cell therapy and autoimmune disease,” said Fred Aslan, M.D.
Neutral
GlobeNewsWire
1 month ago
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA.
Neutral
GlobeNewsWire
2 months ago
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D.
Neutral
GlobeNewsWire
5 months ago
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases
Neutral
GlobeNewsWire
5 months ago
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 3:30 p.m. GMT, in London, UK.
Neutral
GlobeNewsWire
5 months ago
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors.
Neutral
GlobeNewsWire
7 months ago
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, 2024, at 8:00 a.m.
Neutral
GlobeNewsWire
7 months ago
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indications Treated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent progress. “Artiva is at an inflection point as we advance AlloNK® in clinical development across multiple autoimmune indications and transition to a publicly traded company,” said Fred Aslan, M.D.
Charts implemented using Lightweight Charts™